Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis.

Schiopu E, Hsu VM, Impens AJ, Rothman JA, McCloskey DA, Wilson JE, Phillips K, Seibold JR.

J Rheumatol. 2009 Oct;36(10):2264-8. doi: 10.3899/jrheum.090270. Epub 2009 Sep 15.

PMID:
19755613
2.

Bosentan in pulmonary arterial hypertension secondary to scleroderma.

Joglekar A, Tsai FS, McCloskey DA, Wilson JE, Seibold JR, Riley DJ.

J Rheumatol. 2006 Jan;33(1):61-8.

PMID:
16395751
3.

Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosis.

Seibold JR, Clements PJ, Furst DE, Mayes MD, McCloskey DA, Moreland LW, White B, Wigley FM, Rocco S, Erikson M, Hannigan JF, Sanders ME, Amento EP.

J Rheumatol. 1998 Feb;25(2):302-7.

PMID:
9489823
4.

Skin involvement as a relevant outcome measure in clinical trials of systemic sclerosis.

Seibold JR, McCloskey DA.

Curr Opin Rheumatol. 1997 Nov;9(6):571-5. Review.

PMID:
9375287
5.

Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study.

Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr, Steen VD, Varga J, Jimenez S, Mayes M, Clements PJ, Weiner SR, Porter J, Ellman M, Wise C, Kaufman LD, Williams J, Dole W.

Ann Intern Med. 1994 Feb 1;120(3):199-206.

PMID:
7506013
6.

Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.

Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP.

J Rheumatol. 1992 Sep;19(9):1407-14.

PMID:
1279170
7.

Molecular analysis of human argininosuccinate lyase: mutant characterization and alternative splicing of the coding region.

Walker DC, McCloskey DA, Simard LR, McInnes RR.

Proc Natl Acad Sci U S A. 1990 Dec;87(24):9625-9.

Supplemental Content

Loading ...
Support Center